Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...
The core issue was whether the institute was eligible for exemptions under Section 10(23C)(iiiac) and Section 11(2) of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback